PMID- 20697842
OWN - NLM
STAT- MEDLINE
DCOM- 20120322
LR  - 20211020
IS  - 1559-131X (Electronic)
IS  - 1357-0560 (Print)
IS  - 1357-0560 (Linking)
VI  - 28
IP  - 4
DP  - 2011 Dec
TI  - Long-term response with everolimus for metastatic renal cell carcinoma refractory 
      to sunitinib.
PG  - 1527-9
LID - 10.1007/s12032-010-9640-y [doi]
AB  - A 70-year-old man with metastatic renal cell carcinoma developed progressive 
      liver metastases after 8 weeks of treatment with the multitargeted tyrosine 
      kinase inhibitor (TKI) sunitinib. He then participated in the phase III 
      placebo-controlled clinical trial of the oral mammalian target of rapamycin 
      (mTOR) inhibitor everolimus, initially randomized to placebo (but had disease 
      progression after 3 months) and crossed over to everolimus at time of unblinding. 
      The patient had stable disease after 8 weeks (two cycles) of everolimus that was 
      maintained until 28 months of therapy, at which time the patient had achieved a 
      partial response. This case illustrates the potential for patients with 
      metastatic renal cell carcinoma, a malignancy with historically poor prognosis, 
      to derive long-term benefit from everolimus when used in a manner consistent with 
      its approved indication (after TKI therapy with sunitinib or sorafenib).
FAU - Molina, Ana M
AU  - Molina AM
AD  - Genitourinary Service, Division of Medical Oncology and the Department of Medical 
      Imaging, Memorial Sloan-Kettering Cancer Center, New York, NY, USA.
FAU - Ginsberg, Michelle S
AU  - Ginsberg MS
FAU - Motzer, Robert J
AU  - Motzer RJ
LA  - eng
GR  - R25 CA020449/CA/NCI NIH HHS/United States
GR  - T32 CA009207/CA/NCI NIH HHS/United States
GR  - T32 CA009207-35/CA/NCI NIH HHS/United States
PT  - Case Reports
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20100810
PL  - United States
TA  - Med Oncol
JT  - Medical oncology (Northwood, London, England)
JID - 9435512
RN  - 0 (Antineoplastic Agents)
RN  - 0 (Indoles)
RN  - 0 (Pyrroles)
RN  - 9HW64Q8G6G (Everolimus)
RN  - V99T50803M (Sunitinib)
RN  - W36ZG6FT64 (Sirolimus)
SB  - IM
MH  - Aged
MH  - Antineoplastic Agents/*therapeutic use
MH  - Arthritis, Rheumatoid/complications
MH  - Carcinoma, Renal Cell/complications/*drug therapy/secondary
MH  - Clinical Trials, Phase III as Topic
MH  - Everolimus
MH  - Humans
MH  - Hypercholesterolemia/complications
MH  - Hypertension/complications
MH  - Indoles/therapeutic use
MH  - Kidney Neoplasms/complications/*drug therapy/pathology
MH  - Lung Neoplasms/complications/*drug therapy/secondary
MH  - Male
MH  - Pyrroles/therapeutic use
MH  - Randomized Controlled Trials as Topic
MH  - Salvage Therapy/*methods
MH  - Sirolimus/*analogs & derivatives/therapeutic use
MH  - Sunitinib
PMC - PMC3219862
EDAT- 2010/08/11 06:00
MHDA- 2012/03/23 06:00
PMCR- 2010/08/10
CRDT- 2010/08/11 06:00
PHST- 2010/06/18 00:00 [received]
PHST- 2010/07/24 00:00 [accepted]
PHST- 2010/08/11 06:00 [entrez]
PHST- 2010/08/11 06:00 [pubmed]
PHST- 2012/03/23 06:00 [medline]
PHST- 2010/08/10 00:00 [pmc-release]
AID - 9640 [pii]
AID - 10.1007/s12032-010-9640-y [doi]
PST - ppublish
SO  - Med Oncol. 2011 Dec;28(4):1527-9. doi: 10.1007/s12032-010-9640-y. Epub 2010 Aug 
      10.